Colossal Spinoff Astromech Raises $20M as AI Biotech Explodes
anselm · x · 2026-08-21
Colossal Biosciences' spinout Astromech announced a $20M raise at a $3.8B valuation, focusing on AI-assisted drug design and discovery. CEO Ben Lamm predicts a "Precambrian explosion" of new drugs and therapies driven by AI. The company notes that up to 50% of biodiversity is forecast to be lost in the next 25 years, arguing conservation efforts aren't moving fast enough. Colossal has raised $635M to date.
Related event: Astromech, Colossal Spinout, Raises $20M at $3.8B Valuation(2 posts)→
More from Venture
- YC-backed Overshoot launches inference optimization, claims $5M saved for AI teams — ycombinator · 2026-10-16
- Vercel launches Token Pass: $30/mo for $80 of GLM 5.3 and Kimi K3 credits — evilrabbit_ · 2026-10-16
- Polymarket gives Meta just 3% to lead AI by year-end; Anthropic at 44% — Polymarket · 2026-10-16
- Ferryman: solo-built cross-posting SaaS charges $30-$100/mo, syncs via Claude and Codex — KevinNaughtonJr · 2026-10-16
- 6 open models, 80 M&A memos, double-blind AI judges: Step 5 Preview claims a new Pareto frontier — Aizkmusic · 2026-10-16
- Kevin Kwok: Vercel's agent play is 'manufacturing your own customers,' TSMC-style — kevinakwok · 2026-10-16